Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Xue T, Fei S, Gu J, Li N, Zhang P, Liu X, Thompson PR, Zhang X. Inhibiting MEK1 R189 citrullination enhances the chemosensitivity of docetaxel to multiple tumour cells. Philos Trans R Soc Lond B Biol Sci. 2023 11 20; 378(1890):20220246.
-
Kugler BA, Lourie J, Berger N, Lin N, Nguyen P, DosSantos E, Ali A, Sesay A, Rosen HG, Kalemba B, Hendricks GM, Houmard JA, Sesaki H, Gona P, You T, Yan Z, Zou K. Partial skeletal muscle-specific Drp1 knockout enhances insulin sensitivity in diet-induced obese mice, but not in lean mice. Mol Metab. 2023 11; 77:101802.
-
Khor CC, Winter S, Sutiman N, M?rdter TE, Chen S, Lim JSL, Li Z, Li J, Sim KS, Ganchev B, Eccles D, Eccles B, Tapper W, Zgheib NK, Tfayli A, Ng RCH, Yap YS, Lim E, Wong M, Wong NS, Ang PCS, Dent R, Tremmel R, Klein K, Schaeffeler E, Zhou Y, Lauschke VM, Eichelbaum M, Schwab M, Brauch HB, Chowbay B, Schroth W. Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations. Clin Pharmacol Ther. 2023 03; 113(3):712-723.
-
Diot C, Garc?a-Gonz?lez AP, Vieira AF, Walker M, Honeywell M, Doyle H, Ponomarova O, Rivera Y, Na H, Zhang H, Lee M, Olsen CP, Walhout AJM. Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism. Nat Commun. 2022 09 23; 13(1):5595.
-
Li F, Miao L, Xue T, Qin H, Mondal S, Thompson PR, Coonrod SA, Liu X, Zhang X. Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells. J Exp Clin Cancer Res. 2019 Oct 10; 38(1):414.
-
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 09 03; 322(9):857-867.
-
Karlsson E, Veenstra C, G?rsj? J, Nordenskj?ld B, Fornander T, St?l O. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer. J Cancer Res Clin Oncol. 2019 Mar; 145(3):599-607.
-
Dom?nguez-Ord??ez R, Garcia-Ju?rez M, Lima-Hern?ndez FJ, G?mora-Arrati P, Dom?nguez-Salazar E, Blaustein JD, Etgen AM, Gonz?lez-Flores O. Lordosis facilitated by GPER-1 receptor activation involves GnRH-1, progestin and estrogen receptors in estrogen-primed rats. Horm Behav. 2018 02; 98:77-87.
-
Shats I, Deng M, Davidovich A, Zhang C, Kwon JS, Manandhar D, Gord?n R, Yao G, You L. Expression level is a key determinant of E2F1-mediated cell fate. Cell Death Differ. 2017 04; 24(4):626-637.
-
Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8.